featured
Tepotinib for Advanced Solid Cancers Harboring MET Exon 14 Skipping Mutations or Amplifications
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
ESMO Open 2024 Aug 29;9(9)103668, EJ Kang, Y Yang, S Lee, YJ Kim, SM Lim, MJ Ahn, YJ Choi, Y Lee, TM Kim, I Kim, HK Ahn, HC Jeung, SI Lee, SY Oh, WK Bae, H Ryu, KH Park, KH LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.